Octreotide (drug)

DRUG4 trials

Sponsors

Albert Einstein Healthcare Network, University of Alabama at Birmingham, King Faisal Specialist Hospital & Research Center, Lahore General Hospital

Conditions

Diabetes MellitusDiabetic Macular EdemaHepatorenal SyndromeHypoglycemiaSmall-for-Size Syndrome

Phase 1

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

Not yet recruitingNCT06881888

University of Alabama at BirminghamDiabetic Macular Edema

Start: 2026-08-31End: 2027-12-31Target: 60Updated: 2025-10-03

Phase 3

Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia

CompletedNCT00804297

Albert Einstein Healthcare NetworkDiabetes Mellitus, Hypoglycemia

Start: 2005-06-30End: 2007-01-31Target: 40Updated: 2008-12-08

Phase 4

Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)

Not yet recruitingNCT06974344

King Faisal Specialist Hospital & Research CenterSmall-for-Size Syndrome

Start: 2025-06-01End: 2030-09-01Target: 80Updated: 2025-05-15

Unknown Phase

Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome

CompletedNCT07460908

Lahore General HospitalHepatorenal Syndrome

Start: 2025-05-01End: 2025-10-30Updated: 2026-03-10